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Quinolone antimicrobial drugs are widely used due to their broad spectrum and intense bactericidal activity. They are developed for oral and parenteral use in the treatment of bacterial diseases, including severe systemic infections (Brunner and Zeiler, 1988) . Most quinolone antibacterial drugs are rapidly absorbed from the intestine, with a bioavailability of close to 90%, and then penetrate well into most body tissues and fluids. However, some fluoroquinolones have been reported to undergo efflux, which can explain the low bioavailability of some of them; for instance, the bioavailabilities of ciprofloxacin and norfloxacin are 50-80% and 30-40%, respectively (Sörgel et al., 1989; Lamp et al., 1992) . In addition, at least 10% of i.v. administered ciprofloxacin is eliminated by intestinal secretion (Rohwedder et al., 1990) . Only 1% of the dose is excreted into the bile (Parry et al., 1988) . Some studies indicated that intestinal elimination of ciprofloxacin was not mediated by P-glycoprotein (ABCB1) (Griffiths et al., 1993; Cavet et el., 1997; Dautrey et al., 1999) , one of the most important members of the ATP-binding cassette group of transporters, and often involved in restricting the bioavailability of drugs. Accordingly, several groups (Lowes and Simmons, 2002; Michot et al., 2004) have recently shown that ciprofloxacin is not a substrate of this transporter nor of MRP2 (ABCC2), another ABC transporter. However, the pharmacokinetics of ciprofloxacin was suggested to involve one or more active intestinal or hepatobiliary transport mechanisms in rats (Dautrey et al., 1999) .
Norfloxacin and ofloxacin have also been shown to be subject to active efflux (Cao et al., 1992; Rabaa et al., 1996) . Active secretory mechanisms common to all fluoroquinolones have been suggested (Griffiths et al. 1993 (Griffiths et al. , 1994 , as well as competition between fluoroquinolones at transporter sites (Rabaa et al., 1996) .
However, the precise mechanisms involved in the pharmacokinetics of ciprofloxacin and other fluoroquinolones remain to be clarified. Several adverse effects have been reported with the use of quinolones, including nausea, diarrhea, vomiting, dizziness, headache, insomnia and phototoxicity (Stahlmann, 2002) . Arthropathy (condrotoxicity, tendopathies) in immature animals has been observed after administration of all quinolones tested so far. Although the significance of this undesirable side effect for humans remains unclear, the toxic potential has led to the contraindication of quinolones in children and women during pregnancy and lactation. Despite the extensive use of fluoroquinolones, little is known about their secretion into human breast milk. More accurate data on the passage of these compounds into breast milk will allow for the establishment of better recommendations for their use in lactating women (Dan et al., 1993) .
Breast Cancer Resistance Protein (BCRP/ABCG2), another member of the ABC family of transporters, is apically expressed and mediates the active and outward transport of a range of anticancer drugs, dietary compounds, food carcinogens and antibiotics (van Herwaarden et al., 2003; Burger et al., 2004; Merino et al., 2005a) .
BCRP is found not only in tumor cells but also in a variety of normal tissues such as intestine, liver, brain and mammary gland. Several in vivo studies indicated that Bcrp1 mediates the hepatobiliary excretion of its substrates and limits their oral bioavailability and fetal penetration (van Herwaarden et al., 2003; Jonker et al., 2000) . Induced expression of Bcrp1/ BCRP in the lactating mammary gland and an important role of this ABC transporter in the active secretion of several xenobiotics into milk have been demonstrated . Since fluoroquinolone breast milk concentrations are higher than serum concentrations (Giamarellou et al., 1989) , we hypothesized that the pharmacokinetics and milk secretion of these fluoroquinolones could be regulated by BCRP in vivo. ) was from Ovejero (León, Spain); Ko143 was described previously (Allen et al., 2002) . All other compounds used were reagent grade.
Cells and tissue culture. The polarized canine kidney cell line MDCK-II was used in the transport assays. Human BCRP-and murine Bcrp1-transduced MDCK-II subclones were described previously (Jonker et al., 2000; Pavek et al., 2004) . The cells were cultured in DMEM supplied with glutamax (Life Technologies, Inc.) and supplemented with penicillin (50 units/ml), streptomycin (50 µg/ml), and 10% (v/v) fetal calf serum (MP Biomedicals) at 37 o C in the presence of 5% CO 2 . The cells were trypsinized every 3 to 4 days for subculturing.
Transport assays. Transport assays were carried out as described earlier (Merino et al., 2005a) , with minor modifications. Cells were seeded on microporous membrane filters (3.0 µm pore size, 24 mm diameter; Transwell 3414; Costar, Corning, NY) at a density of 1.0 x 10 6 cells per well. Cells were grown for 3 days, and medium was replaced every day. Transepithelial resistance was measured in each well using a as an internal standard in a 1.5 ml reaction tube. The mixture was vortexed vigorously, and 300 µl of dichloromethane were added. Samples were shaken for 60 s and the organic and water phases were separated by centrifugation at 5000 x g for 5 min and evaporated to dryness under a nitrogen stream. The samples were resuspended in 100 µl of methanol and injected into the HPLC system. Samples from the transport assays were not processed and 100 µl of the culture media were directly injected into the HPLC system. The system consisted of a Waters 600 pump, a Waters 717plus autosampler and a Waters 2487 UV detector. Separation of the samples was performed on a reversedphase column (AQUA TM C18 polar encapped, 5-µm particle size, 250 mm x 4.6 mm).
The composition of the mobile phase was 25 mM orthophosphoric acid (pH 3.0)/acetonitrile (77:23). The flow rate of the mobile phase was set to 1.0 ml/min. UV absorbance was measured at 278 nm. Peak area ratios (fluoroquinolone/oxfendazole)
were used for comparison with the standard curve. The integration was performed using the software Millennium 32 (Waters). Standard samples in the appropriate drug-free matrix were prepared yielding a concentration range from 0.08 µg/ml up to 10 µg/ml.
Pharmacokinetic calculations and statistical analysis. The two-sided unpaired
Student's t test was used throughout to assess the statistical significance of differences between the two sets of data. Results are presented as the means ± standard deviations.
Differences were considered to be statistically significant when p < 0.05. AUC from time = 0 to the last sampling point was calculated by the linear trapezoidal rule.
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Results
In vitro transport of fluoroquinolones. We used the polarized canine kidney cell line MDCK-II and its subclones transduced with murine Bcrp1 and human BCRP cDNAs, to test the possible role of murine Bcrp1 and human BCRP in the in vitro transport of ciprofloxacin, ofloxacin and norfloxacin. The parental and transduced cell lines were grown to confluent polarized monolayers on porous membrane filters, and vectorial transport of the fluoroquinolones (10 µM) across the monolayers was determined. In the MDCK-II parental cell line, apically and basolaterally directed translocation were similar (Fig. 1A, 2A and 3A) . In the Bcrp1-transduced MDCK-II cell lines, apically directed translocation was highly increased and basolaterally directed translocation drastically decreased for the three compounds (Fig. 1B, 2B and 3B). When the selective Bcrp1 inhibitor Ko143 was used (Allen et al., 2002) , the Bcrp1/BCRP mediated transport was completely inhibited (Fig. 1C, 1E , 2C, 2E, 3C and 3E), resulting in a vectorial translocation pattern equal to that of the MDCK-II parental cell line. In the human BCRP-transduced cell line, the difference in the directional transport was lower than in the murine Bcrp1-transduced cell line (Fig. 1D, 2D and 3D ). This may be due to an effectively lower level of the human protein in the cell line used, as also suggested by the nearly 5-fold smaller reduction in mitoxantrone accumulation in these cells (see Plasma pharmacokinetics of ciprofloxacin in Bcrp1 -/-and wild-type mice. To assess whether the in vitro Bcrp1-mediated transport of fluoroquinolones was also relevant in vivo, we studied ciprofloxacin pharmacokinetics in Bcrp1 -/-and wild-type male mice. We determined the plasma concentration of ciprofloxacin after its oral and intravenous administration (10 mg/kg) in both types of mice (Fig. 5) . Plasma concentration was more than 2-fold increased in Bcrp1 -/-compared to wild-type mice (1.77 ± 0.73 versus 0.85 ± 0.39 µg/ml, p < 0.01) 15 min after oral administration (Fig.   5A ). In the case of i.v. administration (Fig. 5B) , the AUC of the Bcrp1 -/-was 1.5-fold higher compared with the wild-type mice (48.63 ± 5.66 versus 33.10 ± 4.68 min.µg/ml, p < 0.05). Bcrp1 thus appears to be both an important determinant for the oral availability and the elimination of ciprofloxacin.
Secretion of ciprofloxacin into the milk in Bcrp1
-/-and wild-type mice. To test whether Bcrp1 plays a role in the secretion of fluoroquinolones into milk, ciprofloxacin (10 mg/kg) was administered i.v. to lactating Bcrp1 -/-and wild-type females, and 10 min after administration, milk and blood were collected. The data obtained from the analysis of milk and plasma concentrations are shown in Fig. 6 
Discussion
In this study, we show that three widely used fluoroquinolone antibiotics (ciprofloxacin, ofloxacin and norfloxacin) are transported by Bcrp1/BCRP, and that murine Bcrp1 affects the oral availability, pharmacokinetics and milk secretion of ciprofloxacin. As seen with some other transported Bcrp1/BCRP substrates (unpublished data), these fluoroquinolones are not effective inhibitors of Bcrp1/BCRP.
Our results show efficient in vitro transport of ciprofloxacin, ofloxacin and norfloxacin by murine Bcrp1 and more moderate transport by human BCRP. These apparent differences in efficiency of transport between the murine and human homologues ( Fig., 1 , 2 and 3) may be due to a lower effective expression level of the human BCRP construct compared to Bcrp1 in the cell lines used, as the prototype BCRP substrate mitoxantrone was also less affected in the BCRP-compared to the Bcrp1-expressing cell line (Fig. 4) . However, we cannot exclude that there are differences in the affinity/selectivity of BCRP and Bcrp1 for substrates, as has been hypothesized by Mizuno et al. (2004) .
An additional pathway for secretion of ciprofloxacin in Caco-2 cells, which is distinct from both P-glycoprotein and MRP2, has been suggested (Lowes and Simmons, 2002) . BCRP is a good candidate responsible for the ciprofloxacin secretion in Caco-2 cells, since this cell line also expresses functional BCRP (Xia et al., 2005) .
Our in vivo data suggest that Bcrp1 restricts ciprofloxacin oral bioavailability and contributes to overall ciprofloxacin elimination (Fig. 5) . From the present study, we cannot exclude the presence of additional transporters for these fluoroquinolones.
Basolateral transport mechanisms for ciprofloxacin in intestine and liver have been reported (Griffith et al., 1994) . However, the most obvious apical ABC transporters Pglycoprotein and MRP2 do not appear to transport ciprofloxacin (Lowes and Simmons, This article has not been copyedited and formatted. The final version may differ from this version. are transported by MDR1 and MRP2, demonstrates that multiple ABC transporters could contribute to the overall transepithelial secretion of fluoroquinolones (Lowes and Simmons, 2002) . In any case, BCRP seems to be the secretory mechanism common to at least the three fluoroquinolones tested in this study.
Xenobiotic transport in the mammary gland can have tremendous clinical, toxicological and nutritional implications. Passive and active transport processes are involved in the transfer of many drugs into breast milk. In vitro models of passive drug transfer identify drug protein binding, drug ionization, and fat partitioning as the critical determinants of passive drug transfer (Fleishaker et al., 1987; Begg and Atkinson, 1993) . However, recently, an important role of Bcrp1 in the active secretion and concentration of several drugs and carcinogenic xenotoxins into milk has been established Merino et al., 2005a , van Herwaarden et al., 2005 . Our data clearly demonstrate that the presence of Bcrp1 in the mammary gland is also an important factor in the transfer of fluoroquinolones into the milk, as indicated by the 2-fold higher milk-to-plasma ratio of wild-type compared to Bcrp1 -/-mice (Fig. 6 ).
Extrapolating our data to other species, the ciprofloxacin milk-to-plasma ratio for wildtype mice we measured (3.08 ± 0.92) is close to the value obtained in other species, such as rabbits (3.61) and humans (4.67) (Gardner et al., 1992; Aramayona et al., 1996) , and higher than the predicted milk-to-plasma ratio of 1.5 that physicochemical principles would suggest in human milk (Agatanovic-Kustrin et al., 2002) . This value is similar to the ciprofloxacin milk-to-plasma ratio for Bcrp1 -/-mice (1.59 ± 0.08). All this suggests that our findings may be relevant to other species, including humans.
Milk secretion and pharmacokinetics of another antibiotic, nitrofurantoin, have been recently shown to be highly affected by Bcrp1 (Merino et al., 2005a so far suggest that this transporter could be a very important factor in the study and evaluation of contamination of milk with antibiotics and residues, and in the safety of antibiotic application during lactation.
The data presented here may already have other important biological and therapeutic significance. The expression and function of BCRP is variable, depending on different factors, such as coadministered drugs or natural products (Sugimoto et al., 2005) , gender (Merino et al., 2005b) or genetic polymorphisms (Sparreboom et al., 2004) . Fluoroquinolones are barely metabolized (Montay et al., 1994) , so their potential to be affected in their pharmacokinetics by coadministered BCRP inhibitors may have significant consequences in vivo. The reciprocal situation, inhibition of BCRP by fluoroquinolones, is less probable, since our mitoxantrone accumulation results suggest that fluoroquinolones do not efficiently inhibit Bcrp1/BCRP in vitro (Fig. 4) . However, we cannot completely exclude this possibility when substrates distinct from mitoxantrone would be used. In any case, all these factors could modify the pharmacokinetics and milk secretion of fluoroquinolones and thus their local toxicity, their effect on the newborn and even their bactericidal activity. Fluoroquinolone antibiotic activity is concentration dependent and suboptimal concentrations due to variations (either inter-or intra-individual) in BCRP activity could be associated with insufficient eradication of microorganism and potentially rapid emergence of resistance (Michot et el., 2004) . Finally, elevated concentrations of the fluoroquinolones could increase the incidence of adverse effects not only in adults but also in infants.
